Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer
Intervention: Drug: ZSP1241
Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Not yet recruiting
Feeds
6800 items (6800 unread) in 74 feeds
Acinar Cell Carcinoma
(36 unread)
Acinic Cell Carcinoma
(31 unread)
Adenoid Cystic Carcinoma
(93 unread)
Adrenal Gland Cancer
(466 unread)
Ampulla Of Vater
(39 unread)
Anal Cancer
(765 unread)
Angiosarcoma
(96 unread)
Appendix Cancer
(79 unread)
Bile Duct Cancer
(847 unread)
Brain and CNS
(1073 unread)
Carcinoid
(161 unread)
Endocrine/Neuroendocrine
(801 unread)
Gall Bladder Cancer
(165 unread)
Hemangioendothelioma
(56 unread)
Hepatoblastoma
(78 unread)
Pancreas
(57 unread)
Phyllodes
(57 unread)
PMP and Mucinous Tumors
(22 unread)
Rhabdomyosarcoma
(166 unread)
Sarcoma
(1712 unread)
Trial - Cholangiocarcinoma (53 unread)
-
An Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Posted: November 8th, 2018, 3:00pm GMT
-
Primary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.
Posted: November 5th, 2018, 3:00pm GMT
Condition: Acute Cholecystitis
Interventions: Procedure: EUS-guided gallbladder drainage; Procedure: Non EUS-guided gallbladder drainage
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Recruiting -
Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer
Posted: October 17th, 2018, 2:00pm GMT
Condition: Bile Duct Obstruction, Extrahepatic
Intervention: Diagnostic Test: Cytology staining
Sponsors: Gangnam Severance Hospital; Korea Institute of Science and Technology
Not yet recruiting -
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Posted: October 3rd, 2018, 2:00pm GMT
Conditions: Colorectal Cancer; Cholangiocarcinoma
Interventions: Device: Medtronic pump and Codman catheter; Drug: Floxuridine (FUDR); Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Irinotecan (CPT-11); Drug: Fluorouracil
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Posted: September 26th, 2018, 2:00pm GMT
Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin
Sponsor: Forma Therapeutics, Inc.
Not yet recruiting -
Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer
Posted: September 20th, 2018, 2:00pm GMT
Condition: Nonresectable Bile Duct Cancer
Intervention: Device: Ablation Therapy
Sponsor: Institut Paoli-Calmettes
Recruiting -
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Posted: September 3rd, 2018, 2:00pm GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Not yet recruiting -
Personal Resilience Empowerment Program Study
Posted: August 23rd, 2018, 2:00pm GMT
Conditions: Lung Cancer; Cholangiocarcinoma; Pancreatic Cancer; Liver Cancer
Intervention: Behavioral: Personal Resilience Empowerment Program including 5 sessions with health coaches
Sponsor: Hackensack Meridian Health
Recruiting -
The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
Posted: August 20th, 2018, 2:00pm GMT
Conditions: Pancreas Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Other: Measurement of triceps skinfold thickness
Sponsor: Samsung Medical Center
Recruiting -
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Posted: August 16th, 2018, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Biological: MUC-1 CART cell immunotherapy
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting -
Fluorescence Image Guided Surgery in Cholangiocarcinoma
Posted: August 8th, 2018, 2:00pm GMT
Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Bevacizumab-IRDye800CW; Device: near infrared (NIR) fluorescence imaging
Sponsor: University Medical Center Groningen
Recruiting -
Trastuzumab in HER2-positive Biliary Tract Cancer
Posted: August 2nd, 2018, 2:00pm GMT
Conditions: Cholangiocarcinoma; Biliary Tract Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification
Intervention: Drug: Trastuzumab
Sponsor: Changhoon Yoo
Not yet recruiting -
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
Posted: August 2nd, 2018, 2:00pm GMT
Condition: Gastrointestinal Cancer
Intervention: Other: Surgeon-palliative care team co management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting -
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Posted: July 27th, 2018, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: mFOLFOXIRI
Sponsor: Khon Kaen University
Recruiting -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Posted: July 26th, 2018, 2:00pm GMT
Conditions: HER2-positive Breast Cancer; HER2 Gene Mutation; HER-2 Gene Amplification; HER2 Positive Gastric Cancer; Salivary Gland Cancer; Salivary Gland Tumor; Salivary Gland Carcinoma; Salivary Gland Neoplasms; Lung Cancer; Colo-rectal Cancer; Rare Diseases; Solid Tumor; Recurrent Gastric Cancer; Recurrent Colon Cancer; Recurrent Breast Cancer; Head and Neck Cancer; Head and Neck Carcinoma; Bladder Cancer; Cervical Cancer; Liver Cancer; Bile Duct Cancer; Urologic Cancer; Pancreatic Cancer; Prostate Cancer; Recurrent Prostate Cancer; Rectal Cancer; Recurrent Ovarian Carcinoma; Recurrent Renal Cell Cancer; Rectal Cancer Stage II; Rectal Cancer Stage I; Rectal Cancer Stage III; Skin Cancer; Mouth Cancer; Lip Cancer Stage I; Tongue Cancer; Breast Neoplasm Malignant Primary; Larynx Cancer; Tonsil Cancer; Palate Cancer; Mucoepidermoid Carcinoma; Primary Peritoneal Carcinoma; Mucinous Adenocarcinoma Gastric; Mucinous Breast Cancer Recurrent; Cholangiocarcinoma
Intervention: Drug: A166
Sponsor: Klus Pharma Inc.
Recruiting -
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting -
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
Posted: June 20th, 2018, 2:00pm GMT
Conditions: Breast Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Gastric Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Prostate Carcinoma
Interventions: Other: Interview; Other: Survey Administration
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting -
Fluorescence QRH-882260 Peptide Imaging in the Bile Duct
Posted: February 19th, 2018, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: QRH-882260 Heptapeptide
Sponsors: D. Kim Turgeon, MD; University of Washington
Not yet recruiting -
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Posted: November 13th, 2017, 3:00pm GMT
Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Not yet recruiting -
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors
Posted: November 6th, 2017, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas
Interventions: Drug: CDX-1140; Drug: CDX-301
Sponsor: Celldex Therapeutics
Recruiting -
Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS, and GEM; and CIS and GEM Alone in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenoc
Posted: August 31st, 2017, 2:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic; Gallbladder Adenocarcinoma
Interventions: Drug: PEGPH20; Drug: CIS; Drug: GEM; Drug: Atezolizumab
Sponsor: Halozyme Therapeutics
Recruiting -
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Posted: August 22nd, 2017, 2:00pm GMT
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting -
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Posted: August 15th, 2017, 2:00pm GMT
Conditions: Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer; Cholangiocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: Entinostat; Drug: Nivolumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Bristol-Myers Squibb
Recruiting -
Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures
Posted: July 7th, 2017, 2:00pm GMT
Conditions: Cholangiocarcinoma; Stricture; Bile Duct
Interventions: Procedure: Biopsies of bile duct stricture with pediatric biopsy forceps; Procedure: Biopsies of bile duct stricture with cholangioscopy-directed biopsies
Sponsors: Stanford University; University of Rochester; The University of Texas Health Science Center, Houston
Recruiting -
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Posted: July 2nd, 2017, 2:00pm GMT
Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma
Intervention: Drug: Niraparib
Sponsors: University of Florida; Tesaro, Inc.
Recruiting -
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Posted: June 28th, 2017, 2:00pm GMT
Conditions: Gallbladder Carcinoma; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Cholangiocarcinoma
Interventions: Drug: Atezolizumab; Drug: Cobimetinib; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Posted: April 5th, 2017, 2:00pm GMT
Condition: Neoplasms
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Anetumab ravtansine (BAY94-9343)
Sponsors: Bayer; ImmunoGen, Inc.; MorphoSys AG
Recruiting -
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Posted: March 7th, 2017, 3:00pm GMT
Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting -
A Study of ABBV-181 in Participants With Advanced Solid Tumors
Posted: December 22nd, 2016, 3:00pm GMT
Condition: Advanced Solid Tumors Cancer
Interventions: Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting -
Anti-PD-1 Antibody Alone or in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies
Posted: November 10th, 2016, 3:00pm GMT
Condition: Malignancies Multiple
Interventions: Drug: Anti-PD-1 antibody; Drug: Decitabine
Sponsor: Han weidong
Recruiting -
Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy
Posted: October 5th, 2016, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: INCB054828
Sponsor: Incyte Corporation
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary Origin; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Placental-Site Gestational Trophoblastic Tumor; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Malignant Transformation; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Posted: July 4th, 2016, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting -
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Posted: June 23rd, 2016, 2:00pm GMT
Conditions: Neoplasms; Pancreatic Neoplasms
Interventions: Drug: LMB-100; Drug: Nab-Paclitaxel; Device: Mesothelin Expression
Sponsor: National Cancer Institute (NCI)
Recruiting -
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Posted: June 21st, 2016, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sponsor: Sirtex Medical
Recruiting -
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Posted: May 2nd, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type; Periampullary Adenocarcinoma
Interventions: Procedure: Pancreatectomy; Other: Lavage
Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting -
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
Posted: May 2nd, 2016, 2:00pm GMT
Conditions: Cholangiocarcinoma; Colorectal Adenocarcinoma; Esophageal Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Gastric Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Biological: Adoptive Immunotherapy; Biological: Aldesleukin; Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
Quality of Life in Patients With Primary Sclerosing Cholangitis
Posted: March 18th, 2016, 2:00pm GMT
Condition: Primary Sclerosing Cholangitis
Intervention: Other: quality of life survey
Sponsor: Duke University
Recruiting -
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho
Posted: March 4th, 2016, 3:00pm GMT
Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting -
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Posted: December 16th, 2015, 3:00pm GMT
Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Posted: December 11th, 2015, 3:00pm GMT
Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
Posted: October 29th, 2015, 2:00pm GMT
Condition: Bile Duct Cancer
Interventions: Drug: GEMCIS; Drug: mFolfirinox
Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Federation Francophone de Cancerologie Digestive
Recruiting -
OLAParib COmbinations
Posted: October 15th, 2015, 2:00pm GMT
Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center; The Cleveland Clinic
Recruiting -
Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Posted: October 15th, 2015, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: Larotrectinib LOXO-101
Sponsors: Loxo Oncology, Inc.; Bayer
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting -
90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Posted: July 31st, 2015, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Posted: June 8th, 2015, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Binimetinib; Drug: Capivasertib; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dasatinib; Drug: Defactinib; Drug: FGFR Inhibitor AZD4547; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)
Posted: March 19th, 2015, 2:00pm GMT
Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; UC (Urothelial Cancer); Endometrial Cancer; Multiple Myeloma; MPN (Myeloproliferative Neoplasms); Breast Cancer; Cholangiocarcinoma
Interventions: Drug: INCB054828; Drug: Gemcitabine + Cisplatin; Drug: Pembrolizumab; Drug: Docetaxel; Drug: Trastuzumab
Sponsor: Incyte Corporation
Recruiting -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Posted: May 30th, 2014, 2:00pm GMT
Condition: Advanced Cholangiocarcinoma
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting -
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Posted: May 1st, 2014, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Senhwa Biosciences, Inc.
Recruiting -
A Study of TAS-120 in Patients With Advanced Solid Tumors
Posted: February 3rd, 2014, 3:00pm GMT
Conditions: Cholangiocarcinoma; Brain Tumor; Urothelial Cancer; Other Tumor Types With FGFR2 Gene Fusions; Activating Mutations; FGFR2 Amplification
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
Recruiting -
Integrated Cancer Repository for Cancer Research
Posted: December 16th, 2013, 3:00pm GMT
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; GIST; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; CNS Tumor; CNS Cancer; Mesothelioma; Breastcancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer
Intervention:
Sponsor: University of Nebraska
Recruiting